Natural killer cell subsets differentially reject embryonic stem cells based on licensing

Transplantation

Volumn 97, Issue 10, 2014, Pages 992-998

  Perez Cunningham, Jessica ^a   Ames, Erik ^a   Smith, Rachel C ^a   Peter, Anna K ^a   Naidu, Ridhima ^a   Nolta, Jan A ^a,b   Murphy, William J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Embryonic stem cells; Licensing; NK cells; Stem cell transplantation; Tolerance

Indexed keywords

ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ARTICLE; BIOLUMINESCENCE; CELL DIFFERENTIATION; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY ASSAY; EMBRYONIC STEM CELL; GRAFT REJECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LICENSING; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EMBRYONIC STEM CELLS; GRAFT REJECTION; HUMANS; IMMUNITY, CELLULAR; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84901269125     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000063     Document Type: Article

References (18)

1. Schwartz SD, Hubschman JP, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 2012; 379: 713.
2. Koch CA, Jordan CE, Platt JL. Complement-dependent control of teratoma formation by embryonic stem cells. J Immunol 2006; 177: 4803.
3. Pearl JI, Lee AS, Leveson-Gower DB, et al. Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 2011; 8: 309.
4. Raulet DH. Missing self recognition and self tolerance of natural killer (NK) cells. Semin Immunol 2006; 18: 145.
5. Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005; 436: 709.
6. Bonde S, Zavazava N. Immunogenicity and engraftment of mouse embryonic stem cells in allogeneic recipients. Stem Cells (Dayton, Ohio) 2006; 24: 2192.
7. Drukker M, Katchman H, Katz G, et al. Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells (Dayton, Ohio) 2006; 24: 221.
8. Dressel R, Schindehutte J, Kuhlmann T, et al. The tumorigenicity of mouse embryonic stem cells and in vitro differentiated neuronal cells is controlled by the recipients' immune response. PloS One 2008; 3: e2622.
9. Dressel R, Nolte J, Elsner L, et al. Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells. Faseb J 2010; 24: 2164.
10. Frenzel LP, Abdullah Z, Kriegeskorte AK, et al. Role of natural-killer group 2 member D ligands and intercellular adhesion molecule 1 in natural killer cell-mediated lysis of murine embryonic stem cells and embryonic stem cell-derived cardiomyocytes. Stem Cells (Dayton, Ohio) 2009; 27: 307.
11. Dressel R. Effects of histocompatibility and host immune responses on the tumorigenicity of pluripotent stem cells. Semin Immunopathol 2011; 33: 573.
12. HedlundM, Stenqvist AC, Nagaeva O, et al. Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function. J Immunol 2009; 183: 340.
13. Sun K, Alvarez M, Ames E, et al. Mouse NK cell-mediated rejection of bone marrow allografts exhibits patterns consistent with Ly49 subset licensing. Blood 2012; 119: 1590.
14. Ogasawara K, Benjamin J, Takaki R, et al. Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts. Nat Immunol 2005; 6: 938.
15. Benson DM Jr, Hofmeister CC, Padmanabhan S, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012; 120: 4324.
16. Vey N, Bourhis JH, Boissel N, et al. A phase 1 trial of the antiinhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012; 120: 4317.
17. Pettitt SJ, Liang Q, Rairdan XY, et al. Agouti C57BL/6N embryonic stem cells for mouse genetic resources. Nat Methods 2009; 6: 493.
18. Berg M, Lundqvist A, McCoy P Jr, et al. Clinical-grade ex vivoexpanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009; 11: 341.